Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Tumor-Agnostic 2Other 2Head & Neck 2Genitourinary 2Endocrine 2NET 1

Conditions

Neoplasms 2

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Arginine × Tumor-Agnostic × Clear all
NCT03940053 2019-05-07

Prevention of Cancer Development and Progression

The First Affiliated Hospital of Zhengzhou University

Phase 3 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT02844387 2016-07-28

Supplementation of L-arginine in Patients With Non-resectable Brain Metastases

Instituto de Oncología Ángel H. Roffo

Phase 1/2 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡